• Lymphoma & blood cancers
  • Chronic Lymphocytic Leukaemia (CLL)
Name No. Patient Profile Purpose
CLL13 16-60

Chronic Lymphocytic Leukaemia (CLL).

The purpose of the study is to assess if treatments that do not contain chemotherapy are more effective and have fewer side effects than the standard treatment that contains chemotherapy.


  • Lymphoma & blood cancers
  • Lymphoma
Name No. Patient Profile Purpose
CheckMate 744 17-07

Children, adolescents, and young adults with Classic Hodgkin Lymphoma whose disease has come back or did not respond to initial treatment.

The purpose of this study is to determine whether certain drug combinations are safe and effective.


  • Lymphoma & blood cancers
  • Lymphoma
Name No. Patient Profile Purpose
CHRONOS-4 17-06

Indolent (grow slowly) Non-Hodgkin’s Lymphoma that have returned after previous treatment.

The purpose of this study is to evaluate the efficacy and safety of copanlisib in combination with standard immunochemotherapy.


  • Lymphoma & blood cancers
  • Acute Leukaemia
Name No. Patient Profile Purpose
2215 CL 0301 16-09

Acute Myeloid Leukaemia (AML) with FLT3 Mutation that has returned or is resistant to previous treatment

The purpose of this trial is to determine the clinical benefit of ASP2215 therapy.


  • Lymphoma & blood cancers
  • Lymphoma
Name No. Patient Profile Purpose
CHRONOS-3 15-38

Indolent B-cell non-Hodgkin’s lymphoma that has returned.

The purpose of this trial is to find out if the drug copanlisib in combination with rituximab is superior to placebo in combination with rituximab.


  • Lymphoma & blood cancers
  • Acute Leukaemia
Name No. Patient Profile Purpose
Protocol 04-30 15-36

Myelodysplastic Syndrome after failure of drugs called Hypomethylating Agents

The purpose of this trial is to evaluate whether adding the drug rigosertib to the patient’s doctor’s choice (standard of care treatment) works better and is as safe as the doctor’s choice.